Blood: EPOCH Joint vorinostat treatment of HIV-related non-Hodgkin lymphoma

EPOCH scheme: etoposide (VP-16) 50mg/m2, table jubiting star (E-ADM) 12mg/m2, Changchun new alkali (VCR) 0.4 mg/m2, dissolved in physiological saline 500ml, continuous static drop 2 4h, 1st to 4th day; cyclophosphamide (CTX) 750mg/m2 intravenous injection, 5th day;EPOCH therapy is the preferred option for HIV-NHLs, usually EBV plus or HHV-8 plusHistone deacetylase (HDAC) inhibitor vorinostat can interfere with the incubation period of EBV/HHV-8, enhance chemotherapy-induced cell death, and remove HIV host cellsto assess whether Volino improves epOCH efficacy and/or HIV removal, Ramos et alconducted a randomized second-phase study of 90 HIV-NHLs patients (45 cases in each group), using dose-adjusted EPOCH therapy (if CD20 plus ritrusion) or 300 mg on the first to five days of each cycleStart at most one cycle before full-body chemotherapyThe primary endpoint is the full mitigation rate (CR)the EPOCH group and epOCH-volitamoma (1 cases) were 74% and 68% of patients in 86 assessable percemeable large B-cell lymphoma (61 cases), plasma-female lymphoma (15 cases), primary fluid lymphoma (7 cases), unclassified B-cell NHL (2 cases) and Burkitlyoma (1 case)The CR rate was lower in patients with CD4-plus cell count 200 cells/mm3Compared to EPOCH, EPOCH in combination with Volino did not eliminate HIV host cells and led to more frequent stage 4 neutropenocytic cell reduction and thrombocytromatin (47% and 29% vs 20% and 2%)the overall survival rate and event-free survival (EFS) were similar between the two groupsOverall, there was a significant decrease in EFS in myc-DLBCL patients (44% in 3 years, compared with 83% for Myc-DLBCL)Low diagnostic-treatment intervals (DTI) were also associated with poor prognosis, and pre-trial treatment had no negative effectsin general, EPOCH has a wide range of effects on highly invasive HIV-NHLs, while Volino has no benefit;